Cognitive Assessment Tools for Huntington's Disease. (NCT06546488)
Cognitive Assessment Tools for Individuals With Huntington's Disease.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.
Who can join: Review the eligibility criteria below.
Location: The Ohio State University Wexner Medical Center — Columbus, Ohio
Age range: 30 Years to 65 Years
🧪 Interventions in This Study
- Assessments (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- The Ohio State University Wexner Medical Center — Columbus, Ohio
📞 Contact the Study Coordinator
Phone: (614) 366-8642
Email: nicole.vrettos@osumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Huntington Disease
- Neurobiological Predictors of Huntington's Disease (PREDICT-HD) — Iowa City, Iowa
- Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease — Nashville, Tennessee
- GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease — Birmingham, Alabama
- An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) — Clayton,
- Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) — Charlottesville, Virginia
- Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease — Rochester, New York
Explore by condition: All Huntington Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.